Last updated: February 27, 2026
What are the key excipients used in Allegra-D 24 Hour?
Allegra-D 24 Hour combines fexofenadine hydrochloride and pseudoephedrine sulfate. Its formulation primarily includes excipients that support stability, bioavailability, and patient compliance. The core excipients include:
- Microcrystalline cellulose: Filler and binder providing powder integrity.
- Corn starch: Disintegrant, facilitating capsule or tablet breakup.
- Magnesium stearate: Lubricant ensuring manufacturing flow.
- Hydroxypropyl methylcellulose (HPMC): Film-forming agent in coated tablets, affecting release profile.
- Sodium starch glycolate: Superdisintegrant enhancing dissolution.
- Lactose monohydrate: Filler, up to formulation-specific levels.
- Colorants and coloring agents: For branding, compliance with regulations.
The formulation's complexity varies between immediate-release tablets and controlled-release forms, which may include additional or alternative excipients like ethylcellulose or ethyl oleate for sustained release.
How does excipient choice influence Allegra-D's product profile?
Excipient selection impacts:
- Bioavailability: Disintegrants like sodium starch glycolate improve dissolution of active ingredients.
- Stability: Excipients such as magnesium stearate and HPMC affect shelf life.
- Manufacturing: Flow properties contributed by microcrystalline cellulose facilitate high-speed production.
- Patient compliance: Coatings and flavoring agents improve palatability and ease of swallowing.
Enhanced excipient profiles can lead to improved bioavailability or extended release, offering competitive advantages in efficacy or dosing convenience.
What are the commercial opportunities influenced by excipient strategies?
The excipient strategy can open several market opportunities:
- Extended-release formulations: Developing controlled-release versions with novel excipients like ethylcellulose may allow once-daily dosing, appealing to patient preference and strategic differentiation.
- Pediatric or special populations: Reformulating Allegra-D with excipients suitable for children or sensitive groups enables expansion into niche markets.
- Combination products: Incorporating additional excipients to create combination therapies with other antihistamines or decongestants enhances therapeutic options.
- Sustained-release delivery systems: Using biodegradable or bioadhesive excipients can increase drug retention and compliance, attracting blockbuster potential.
- Regulatory incentives: Formulations with novel excipients may qualify for patent extensions or exclusivity periods under certain jurisdictions.
What are challenges in excipient development for Allegra-D?
- Regulatory constraints: New excipients or novel formulations face approval hurdles and lengthy review processes (FDA, EMA).
- Manufacturing complexity: Formulations with advanced excipients require process validation and scale-up adjustments.
- Cost implications: Rare or specialized excipients may increase manufacturing costs, impacting pricing strategies.
- Stability and compatibility: Ensuring excipient compatibility with active ingredients over shelf life remains critical.
- Patent landscape: Novel excipient use may trigger patent disputes or require licensing.
How does competition influence formulation and excipient choices?
Competitive products often employ proprietary or innovative excipients to differentiate:
- Claritin-D: Similar antihistamine-decongestant with different excipient profiles, focusing on fast onset or extended duration.
- Zyrtec-D: Marketed with specific excipient choices aimed at quick dissolution.
- Simultaneous multi-drug formulations: Using excipients that support multi-active ingredient stability and compatibility expands therapeutic scope.
Formulators must balance innovation, regulatory compliance, and cost-effectiveness to sustain market share.
Summary table of formulation and market considerations
| Aspect |
Details |
Implication for Allegra-D |
| Excipient function |
Disintegration, stabilization, bioavailability |
Selection influences efficacy, shelf life, patient experience |
| Formulation types |
Immediate-release, controlled-release, multiparticulate |
Enables market segmentation and premium pricing |
| Regulatory environment |
Stricter for novel excipients |
Drives innovation versus compliance balance |
| Market needs |
Allergic rhinitis, sinus congestion |
Guides formulation focus and optimized excipient use |
| Competition |
Existing patents and formulations |
Necessitates unique excipient choices for differentiation |
Key Takeaways
- Excipient selection in Allegra-D integrates stability, bioavailability, and manufacturability, deeply influencing product performance.
- Developing extended-release and niche formulations offers avenues for market expansion and premium pricing.
- Regulatory hurdles and manufacturing costs pose challenges to innovation with new excipients.
- Patent opportunities exist with novel excipient use, providing strategic exclusivity.
- Competitive differentiation hinges on excipient-based formulation innovations aligned with market needs.
FAQs
1. Can new excipients extend Allegra-D's patent life?
Yes. Incorporating novel excipients or delivery systems can support patent extensions by creating distinct formulations.
2. What excipients are considered for sustained-release Allegra-D formulations?
Ethylcellulose, hydroxypropyl methylcellulose (HPMC), and ethyl oleate are common for sustained-release matrices.
3. How do excipients affect Allegra-D's shelf life?
Excipients like magnesium stearate and proper packaging materials prevent moisture and oxidative degradation, extending shelf life.
4. Are there regulatory limits on excipient types in Allegra-D?
Yes. Agencies like FDA and EMA restrict certain excipients, especially for pediatric or sensitive populations, and require compatibility and safety data.
5. What commercial strategies leverage excipient innovation in Allegra-D?
Creating formulations with improved bioavailability, extended duration, or easier administration addresses unmet needs and commands premium pricing.
References
[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2021). Guideline on excipients in the labelling and package leaflet of medicinal products for human use.
[3] Chen, H., & Li, R. (2022). Formulation strategies for antihistamine drugs. International Journal of Pharmaceutics, 612, 121491.
